België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

negma benelux sa-nv - troxerutine 1 g - poeder voor drank - troxerutine 1 g - troxerutin, combinations

Europese Unie - Nederlands - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastische middelen - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukemie, lymfocytisch, chronisch, b-cel - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Europese Unie - Nederlands - EMA (European Medicines Agency)

eli lilly nederland b.v. - pirtobrutinib - lymfoom, mantel-cel - proteïne kinase remmers - treatment of mantle cell lymphoma (mcl).

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - hydroxyethyl-o-(bèta-)-rutoside 300 mg - capsule, hard - 300 mg - hydroxyethyl-o-(bèta-)-rutoside 324 mg - troxerutin, combinations

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - hydroxyethyl-o-(bèta-)-rutoside 1000 mg - poeder voor oraal gebruik - 1000 mg - hydroxyethyl-o-(bèta-)-rutoside 1000 mg - troxerutin, combinations

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - hydroxyethyl-o-(bèta-)-rutoside 500 mg - tablet - 500 mg - hydroxyethyl-o-(bèta-)-rutoside 500 mg - troxerutin, combinations

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

healthypharm b.v. van de reijtstraat 31-e 4814 ne breda - hydroxyethylrutosiden 500 mg/stuk - tablet - macrogol 6000 ; magnesiumstearaat (e 470b), - rutoside, combinations

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

medcor pharmaceuticals b.v. - hydroxyethylrutosiden; - tablet - rutoside, combinations